Biosimilar Monoclonal Antibodies Market Forecast 2016-2026 : Biosimilar Versions of Infliximab, Rituximab, Trastuzumab, Adalimumab, Bevacizumab and Abciximab

バイオシミラー・モノクローナル抗体の世界市場:インフリキシマブ、リツキシマブ、トラスツズマブ、アダリムマブ、ベバシズマブ、アブシキシマブ

◆タイトル:Biosimilar Monoclonal Antibodies Market Forecast 2016-2026 : Biosimilar Versions of Infliximab, Rituximab, Trastuzumab, Adalimumab, Bevacizumab and Abciximab
◆商品コード:VGAIN6041527
◆調査・発行会社:visiongain
◆発行日:2016年2月
◆ページ数:203
◆レポート形式:PDF / 英語
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名利用)GBP1,999 ⇒換算¥301,849見積依頼/購入/質問フォーム
Five UserGBP2,999 ⇒換算¥452,849見積依頼/購入/質問フォーム
Site License(全社内共有可)GBP4,999 ⇒換算¥754,849見積依頼/購入/質問フォーム
※Single UserとDept Licence(Five User)の場合、DRM(デジタル著作権管理)付PDFファイルです。認証されたPC上のみでの閲覧と、PDF閲覧期限は購入日より1年となります。Dept Licence(Five User)は印刷できますが、Single Userは印刷できません。Site Licence/Global Site Licenseの場合は、閲覧・印刷制限はありません。
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はvisiongainの日本における正規販売代理店です。

【レポートの概要】

本調査レポートでは、"バイオシミラー・モノクローナル抗体の世界市場:インフリキシマブ、リツキシマブ、トラスツズマブ、アダリムマブ、ベバシズマブ、アブシキシマブ"について調査・分析し、レポートサマリー、市場動向、世界市場規模・市場予測、地域別市場分析、主要国別市場分析、専門家の見解、主要企業分析、結論などの情報をお届けいたします。

You need a single report that pulls together best practice, forecasts, primary research and sales figures of biosimilar monoclonal antibodies all in one place. This report provides you with that vital information and it does it, today.
Our new report discusses issues and events affecting the biosimilar monoclonal antibody market.

You will find discussions, including qualitative analyses on:
• Patent expiries and how they will affect the market
• Newly published guidelines on biosimilarity by the Chinese FDA and the US FDA
• The challenges facing the market, including the complexity of the molecules and the use of biobetters
• How demand in emerging markets for cheap drugs will fuel demand
• How clinician and patient confidence in biosimilar monoclonal antibodies will affect the rate of adoption

Biosimilar Monoclonal Antibodies Market Forecast 2016-2026: Biosimilar Versions of Infliximab, Rituximab, Trastuzumab, Adalimumab, Bevacizumab and Abciximab

Convergence and co-ordination of regulatory guidelines between national markets will help to clarify what manufacturers need to do in order to get their products released across multiple market places. Unified global guidelines will also help to prevent market fragmentation, as is the case at present in India. Many biosimilar mAbs have been released here as the regulatory guidelines are not as stringent as those in more developed markets. Demand will be fuelled by the need for cheaper drugs as healthcare budgets become increasingly strained by growing populations, and ageing demographics associated with a greater prevalence of cancer amongst other indications.

Our 203 page report provides 72 tables and 72 figures covering 6 leading submarkets and 13 national markets. Discover the most lucrative areas in the industry and the future market prospects. You will see financial results, interviews, trends, opportunities, and revenue predictions. Increasing development and use of biosimilar monoclonal antibodies will increase worldwide sales of such products from 2016 to 2026, our study shows.

Read the full transcript of 2 exclusive expert opinion interviews from industry specialists informing your understanding and allowing you to assess prospects for investments and sales:
- Dr Seoyoung Kim, Assistant Professor of Medicine at Harvard Medical School and Associate Physician, Brigham and Women’s Hospital
- Professor Steve Morgan, expert in pharmaceutical policy and Professor of health policy in the School of Population and Public Health, University of British Columbia

Who should read this report: directors of:
- Biosimilars
- Biosimilar monoclonal antibodies
- Monoclonal antibodies
- Regulatory bodies
- Biobetters
- CMOs

What are the prospects in the leading regions and countries?
In our study you will find individual revenue forecasts to 2026 for the leading regional and national markets:
• US
• Japan
• Germany
• France
• UK
• Spain
• Italy
• China
• India
• Brazil
• Russia
• South Korea
• Rest of the World

【レポートの目次】

1. Report Overview
1.1 Overview of Biosimilar Monoclonal Antibodies: R&D, Industry and Market
1.2 Why You Should Read this Report
1.3 How This Study Delivers
1.4 Main Questions Answered by the Analysis
1.5 Who is This Investigation For?
1.6 Method of Research and Analysis
1.7 Frequently Asked Questions (FAQs)
1.8 Associate visiongain Reports
1.9 About visiongain

2. Introduction to Biosimilar Monoclonal Antibodies
2.1 Natural Antibodies: Key to the Immune System
2.2 From Serum therapy to Monoclonal Antibodies
2.3 Humanising the mAb
2.4 Biologics (Biological Drugs) and Biosimilars
2.5 Why are Biosimilars in High Demand?
2.6 Considerations for the Development of Biosimilars
2.6.1 Biologics and Biosimilars Are Large, Complex Molecules
2.6.2 How Much of a Concern is Immunogenicity?
2.7 Biosimilar Monoclonal Antibodies Currently on the Market

3. The Global Market for Biosimilar Monoclonal Antibodies, 2016-2026
3.1 The Present Global Market for Biosimilar Monoclonal Antibodies
3.2 The Global Market for Biosimilar mAbs: A Revenue Forecast, 2016-2026
3.3 The Global Market for Biosimilar mAbs by Compound: Predictions for Revenue and Market Share in 2020 and 2026
3.4 The World Market for Biosimilar mAbs by Compound: Revenue Forecasts, 2016-2026
3.4.1 Will Biosimilar Versions of Monoclonal Antibodies Capture a Large Proportion of the Market?
3.4.2 Biosimilar Infliximab: Currently the Second Largest Submarket
3.4.2.1 Biosimilar Infliximab Revenue Forecast 2016-2026
3.4.3 Biosimilar Rituximab: The current Leading Submarket Driven by Sales in Russia
3.4.3.1 Biosimilar Rituximab: Revenue Forecast 2016-2026
3.4.4 Biosimilar Abciximab: Revenue Forecast 2016-2026
3.4.4.1 Biosimilar Abciximab: Revenue Forecast, 2016-2026
3.4.5 Biosimilar Trastuzumab: Pipeline Rich in Phase III Candidates
3.4.5.1 Biosimilar Trastuzumab: Revenue Forecast, 2016-2026
3.4.6 Biosimilar Adalimumab: Patents Hold Back Revenue on a Large Pipeline
3.4.6.1 Biosimilar Adalimumab: Revenue Forecast 2016-2026
3.4.7 Biosimilar Bevacizumab: Will Late Entry to the Biosimilar mAb Market Restrict Revenue?
3.4.7.1 Biosimilar Bevacizumab: Revenue Forecast, 2016-2026
3.5 Drivers and Restraints for the Biosimilar mAb market 2016-2026
3.5.1 Driving Factors of the Biosimilar mAb Market 2016-2026
3.6 Restraining Factors of the Biosimilar mAb Market 2016-2026

4. Individual Biosimilar mAb Products: Marketed and Pipeline Drugs, 2016-2026
4.1 Biosimilar mAbs on the Market in 2015
4.1.1 Celltrion’s Remsima/ Hospira’s Inflectra. Egis’ Flammegis (Infliximab): The First Official Biosimilar Monoclonal Antibody
4.1.1.1 Remsima/Inflectra/Flammegis Revenue Forecast, 2016-2026
4.1.2 Infimab (Infliximab): Launched a Quarter Ahead of Schedule
4.1.2.1 Infimab Revenue Forecast ($m) 2016-2026
4.1.2.2 Dr Reddy’s Reditux (Rituximab): No Application for EU or US Approval
4.1.2.3 Reditux Revenue Forecast, 2016-2026
4.1.3 Intas Pharmaceuticals’ Mabtas (Rituximab)
4.1.3.1 Mabtas (Rituximab) Revenue Forecast 2016-2026
4.1.4 AcellBia (Rituximab): Sales in Russia Generating Large Revenue Figures
4.1.4.1 AcellBia Revenue Forecast 2016-2026
4.1.5 MABALL: Faces Competition from other Biosimilar Rituximabs in India
4.1.5.1 MABALL Revenue Forecast, 2016-2026
4.1.6 Isu Abxis’ Clotinab (abciximab):
4.1.6.1 Clotinab Revenue Forecast, 2016-2026
4.1.7 AbcixiRel: The First Indian Abciximab Biosimilar
4.1.7.1 AbcixiRel Revenue Forecast 2016-2026
4.1.8 Herzuma (Trastuzumab): Approved in South Korea
4.1.8.1 Herzuma Revenue Forecast 2016-2026
4.1.9 CANMAb/Hertraz (Trastuzumab)
4.1.9.1 CANMAb/Hertraz Revenue Forecast, 2016-2026
4.2 Pipeline Biosimilars
4.2.1 BI695500 (Rituximab): An EU Launch Anticipated in 2017
4.2.1.1 BI695500 Revenue Forecast, 2016-2026
4.2.2 CT-P10 (Rituximab): Celltrion’s Reputation for Biosimilars will Assist Sales
4.2.2.1 Celltrion’s CT-P10 (Rituximab) Revenue Forecast, 2016-2026
4.2.3 Boehringer Ingelheim’s BI695501 (Adalimumab)
4.2.3.1 BI695501 Revenue Forecast, 2016-2026
4.2.4 BCD-022 (Trastuzumab): Currently under Development in Russia Only
4.2.4.1 BCD-022 Revenue Forecast, 2016-2026
4.2.5 Fujifilm Kyowa Kirin Biologics’ FKB327 (Adalimumab)
4.2.5.1 FKB327 Revenue Forecast, 2016-2026
4.2.6 Fujifilm Kyowa Kirin Biologics’ FKB238 (Bevacizumab)
4.2.6.1 Fujifilm Kyowa Kirin Biologics’ FKB238 Revenue Forecast 2016-2026
4.2.7 BCD-021 (Bevacizumab): Russia Will Contribute the Most Revenue
4.2.7.1 BCD-021 Revenue Forecast 2016-2026

5. Leading National Markets for Biosimilar Monoclonal Antibodies
5.1 What Were the Leading National Markets for Biosimilar mAbs in 2015?
5.2 How Will National Market Shares Change Over the Forecast Period?
5.3 India: The Current Leading Nation for Biosimilar mAbs but Growth will Slow
5.3.1 India Releases New Biosimilar Development Guidelines
5.3.2 Indian Biosimilar Submarket Forecast 2016-2026
5.4 Russia: Lack of Regulatory Framework Works Well in the Short Term
5.4.1 Russian Government Backed ‘Pharma 2020’ Initiative
5.4.2 Russian Biosimilar mAb Revenue Forecast, 2016-2026
5.4 South Korean Market has Benefitted from Early Biosimilar Guidelines
5.4.1 Significant Investment in Biosimilars in South Korea
5.4.2 South Korean Biosimilar mAb Revenue Forecast, 2016-2026
5.5 China: A Fragmented Biosimilar mAb Market
5.5.1 Chinese FDA Publishes Finalised Biosimilar Guidelines in 2015
5.5.2 China Biosimilar mAb Revenue Forecast, 2016-2026
5.6 Brazil: ANVISA’s Biosimilar Regulations Are Similar the EMA’s
5.6.1 Brazil Biosimilar mAb Revenue Forecast 2016-2026
5.7 The Outlook for Biosimilar mAbs in the EU 2016-2026
5.7.1 Updating Biosimilar Regulation: Guidelines for the Specific Approval of Biosimilar mAbs
5.7.2 Biosimilar mAbs in the EU5: Revenue Forecasts, 2016-2026
5.7.3 Germany: the Current EU Leader
5.7.4 France: Will the Uptake of Biosimilar mAbs be Restricted?
5.7.5 UK: NICE Recommends Use of Remsima for Certain Indications
5.7.6 Italy: Healthcare Spending Cuts Will Drive Growth
5.7.7 Spain: High Biosimilar mAb Discounts Expected
5.8 The Outlook for Biosimilar mAbs in Japan
5.8.1 Regulations for Naming Biosimilars
5.8.2 Biosimilar mAb Market Activity in Japan
5.8.3 Japanese Biosimilar Submarket Forecast 2016-2026
5.9 US Biosimilar mAb Outlook: None Currently on the Market
5.9.1 US FDA Biosimilar Guidelines were Released in 2015
5.9.2 Legal Challenges for Biosimilars in the US
5.9.3 State Regulation of Biosimilar Substitution
5.9.4 The US Biosimilar mAb Market Revenue Forecast, 2016-2026

6. Leading Companies in Biosimilar Monoclonal Antibodies
6.1 Collaboration in Biosimilar mAb Development
6.2 BioXpress: Targeting Patent Expiry Dates in 2019-2023
6.3 Celltrion: Company’s Market Value Surges to Exceed $10.7bn
6.4 Harvest Moon: Six Compounds Under Development
6.5 Genor Biopharma: A Biosimilar mAb Market Leader in China
6.6 Samsung Bioepsis
6.7 Mabion: Poland’s Leading Biosimilar mAb Developer
6.8 Gene Techno Science: Substantial Revenue Increases Since 2014
6.9 India’s Biocon:
6.10 Coherus Biosciences
6.11 BIOCAD: World Leader Biosimilar Rituximab Sales
6.12 Big Pharma and the Biosimilar mAb Market
6.13 Significant Acquisitions in the Biosimilar mAb Market
6.13.1 Pfizer Acquires Hospira
6.13.2 Epirus Acquires Bioceros

7. Qualitative Analysis of Biosimilar Monoclonal Antibodies
7.1 Strengths and Weaknesses of the Biosimilar Monoclonal Antibody Market, 2016-2026
7.1.1 Global Demand for Affordable Biopharmaceuticals has Never Been Greater
7.1.2 Adoption of Biosimilar mAbs will be Proportional to the Rate of Discount
7.1.3 Approval Pathways are Now Established in Developed Markets
7.1.4 Complexity of Protein Molecules Leads to Technical Challenges
7.1.5 Doctor and Patient Confidence May Take Time
7.2 Opportunities and Threat Facing the Biosimilar Monoclonal Antibody Market, 2016-2026
7.2.1 Market Opportunities from Patent Expiries and a Well-stocked Pipeline
7.2.2 Substitution may Not Occur Automatically
7.2.3 Biobetters Offer a Serious Threat to the Production and Uptake of Biosimilars
7.3 Social and Technological Forces Influencing the Biosimilar Monoclonal Antibodies Market 2016-2026
7.3.1 Social Factors: Driving or Restraining the Market?
7.3.2 Technological Factors Concentrate on Reducing Costs and Increasing Ease of Production
7.3.3 Economic Pressures Raise Demand for Biosimilar mAbs
7.3.3.1 Fragmentation of the Market Could Limit Individual Drug Revenues
7.3.4 Political Issues: Stringent Regulations Hurdles to Market Entry

8. Research Interviews
8.1 Interview with Professor Steve Morgan, UBC
8.1.1 On the Benefits of mAbs
8.1.2 On the FDA Biosimilar Regulatory Pathway
8.1.3 On the Challenges in Bringing Biosimilar mAbs to Market
8.1.4 On the Rate of Uptake of Biosimilar mAbs
8.1.5 On What Can be Learnt From Previous Case Studies
8.2 Interview with Dr. Seoyoung C. Kim, Harvard
8.2.1 On the use of Remsima in Korea
8.2.2 On Adoption Rates of Biosimilar Infliximab in the US
8.2.3 On the Indications for Biosimilar Infliximab

9. Conclusions From our Study
9.1 Biosimilar Monoclonal Antibodies: World Market, 2016-2026
9.2 Future of Compounds on the Market and in the Pipeline
9.3 Leading National Markets for Biosimilar Monoclonal Antibodies 2016-2026
9.4 Leading Companies in the Biosimilar mAb Market
9.5 Current and Expected Industry Trends 2016-2026
9.5.1 Cost Control of Healthcare Will Work in Favour mAbs
9.5.2 Upcoming Patent Expiries in Developed Markets Offer Large Market Potential
9.5.3 Complex Production Processes are a Restraining Factor
9.5.4 Clinician and Patient Confidence Must be Maximised to Ensure Uptake
9.5.5 Biobetters Pose a Threat

Visiongain Report Sales Order Form
Appendix A
About Visiongain
Appendix B
Visiongain report evaluation form

List of Tables
Table 1.1 Biosimilar mAbs: Global Revenue Forecast by Reference Compound 2016-2026
Table 2.1 Classification of Monoclonal Antibodies
Table 2.2 Murine Monoclonal Antibodies on the Market, 2016
Table 2.3 Chimeric Monoclonal Antibodies on the Market, 2016
Table 2.4 Humanised Monoclonal Antibodies on the Market, 2016
Table 2.5 Fully Human Monoclonal Antibodies on the Market, 2016
Table 2.6 Revenue of Originator Monoclonal Antibody Products in 2014
Table 3.1 Biosimilar mAb Global Market: Revenue Forecast ($m), 2016-2026
Table 3.2 Global Market for Biosimilar mAbs: Revenues ($m) and Market Shares (%) by Reference Compound, 2015, 2020 and 2026
Table 3.3 EU and US Patent Expiry Dates for the Main mAb Reference Products
Table 3.4 Biosimilar mAbs: Global Revenue Forecast by Reference Compound 2016-2026
Table 3.5 Biosimilar Infliximab: Compounds Awaiting Approval in the Pipeline
Table 3.6 Biosimilar Infliximab: Global Revenue Forecast ($m), AGR (%) and CAGR (%) 2016-2026
Table 3.7 Biosimilar Rituximab: Compounds Marketed and in the Pipeline, 2016
Table 3.8 Biosimilar Rituximab: Global Revenue Forecast ($m), AGR (%) and CAGR (%) 2016-2026
Table 3.9 Biosimilar Abciximab: Compounds Marketed and in the Pipeline, 2016
Table 3.10 Biosimilar Abciximab: Global Revenue Forecast ($m), AGR (%) and CAGR (%) 2016-2026
Table 3.11 Biosimilar Trastuzumab: Compounds Marketed and in the Pipeline, 2016
Table 3.12 Biosimilar Trastuzumab: Global Revenue Forecast ($m), AGR (%) and CAGR (%) 2016-2026
Table 3.13 Biosimilar Adalimumab: Compounds Marketed and in the Pipeline, 2016
Table 3.14 Biosimilar Adalimumab: Global Revenue Forecast 2016-2026
Table 3.15 Biosimilar Bevacizumab: Compounds Marketed and in the Pipeline, 2016
Table 3.16 Biosimilar Bevacizumab: Global Revenue Forecast ($m), AGR (%) and CAGR (%) 2016-2026
Table 4.1 Biosimilar mAbs on the Market in 2015: Revenues ($m) and Market Shares (%)
Table 4.2 Remsima/Inflectra/Flammegis (Infliximab) Forecast: Revenue ($m), Market Share (%), AGR (%) and CAGR (%), 2016-2026
Table 4.3 Infimab (Infliximab) Forecast: Revenue ($m), Market Share (%), AGR (%) and CAGR (%), 2016-2026
Table 4.4 Reditux (Rituximab) Forecast: Revenue ($m), Market Share (%), AGR (%) and CAGR (%), 2016-2026
Table 4.5 Mabtas (Rituximab) Forecast: Revenue ($m), Market Share (%), AGR (%) and CAGR (%), 2016-2026
Table 4.6 Biocad Distribution Partners for AcellBia, 2016
Table 4.7 AcellBia (Rituximab) Forecast: Revenue ($m), Market Share (%), AGR (%) and CAGR (%), 2016-2026
Table 4.8 MABALL (Rituximab) Forecast: Revenue ($m), Market Share (%), AGR (%) and CAGR (%), 2016-2026
Table 4.9 Clotinab (Abciximab) Forecast: Revenue ($m), Market Share (%), AGR (%) and CAGR (%), 2016-2026
Table 4.10 AbcixiRel (Abciximab) Forecast: Revenue ($m), Market Share (%), AGR (%) and CAGR (%), 2016-2026
Table 4.11 Herzuma (Trastuzumab) Forecast: Revenue ($m), Market Share (%), AGR (%) and CAGR (%), 2016-2026
Table 4.12 CANMAb/Hertraz (Trastuzumab) Forecast: Revenue ($m), Market Share (%), AGR (%) and CAGR (%), 2016-2026
Table 4.13 BI695500 (Rituximab) Forecast: Revenue ($m), Market Share (%), AGR (%) and CAGR (%), 2016-2026
Table 4.14 CT-P10 (Rituximab) Forecast: Revenue ($m), Market Share (%), AGR (%) and CAGR (%), 2016-2026
Table 4.15 BI695501 (Adalimumab) Forecast: Revenue ($m), Market Share (%), AGR (%) and CAGR (%), 2016-2026
Table 4.16 BCD-022 (Trastuzumab) Forecast: Revenue ($m), Market Share (%), AGR (%) and CAGR (%), 2016-2026
Table 4.17 FKB327 (Adalimumab) Forecast: Revenue ($m), Market Share (%), AGR (%) and CAGR (%), 2016-2026
Table 4.18 FKB238 (Bevacizumab) Forecast: Revenue ($m), Market Share (%), AGR (%) and CAGR (%), 2016-2026
Table 4.19 BCD-021 (Bevacizumab) Forecast: Revenue ($m), Market Share (%), AGR (%) and CAGR (%), 2016-2026
Table 5.1 Leading National Markets for the Global Biosimilar mAb Industry, 2015
Table 5.2 Leading National Markets for the Global Biosimilar mAb Industry, 2016-2026
Table 5.3 The Indian Biosimilar MAb Market: Revenue ($m), Annual Growth (%) and CAGR (%) Forecast, 2016-2026
Table 5.4 The Russian Biosimilar mAb Market: Revenue ($m), Annual Growth (%) and CAGR (%) Forecast, 2016-2026
Table 5.5 The South Korean Biosimilar mAb Market: Revenue ($m), Annual Growth (%) and CAGR (%) Forecast, 2016-2026
Table 5.6 The Chinese Biosimilar mAb Market: Revenue ($m), Annual Growth (%) and CAGR (%) Forecast, 2016-2026
Table 5.7 The Brazilian Biosimilar mAb Market: Revenue ($m), Annual Growth (%) and CAGR (%) Forecast, 2016-2026
Table 5.8 The EU5 Biosimilar mAb Market: Revenue Forecast ($m), 2016-2026
Table 5.9 The German Biosimilar mAb Market: Revenue ($m), Annual Growth (%) and CAGR (%) Forecast, 2016-2026
Table 5.10 The French Biosimilar MAb Market: Revenue ($m), Annual Growth (%) and CAGR (%) Forecast, 2016-2026
Table 5.11 The UK Biosimilar mAb Market: Revenue ($m), Annual Growth (%) and CAGR (%) Forecast, 2016-2026
Table 5.12 The Italian Biosimilar mAb Market: Revenue ($m), Annual Growth (%) and CAGR (%) Forecast, 2016-2026
Table 5.13 The Spanish Biosimilar MAb Market: Revenue ($m), Annual Growth (%) and CAGR (%) Forecast, 2016-2026
Table 5.14 The Japanese Biosimilar mAb Market: Revenue ($m), Annual Growth (%) and CAGR (%) Forecast, 2016-2026
Table 5.15 Finalised FDA Biosimilar Guidelines, 2015
Table 5.16 The US Biosimilar mAb Market: Revenue ($m) and Annual Growth (%) Forecast, 2016-2026
Table 6.1 Companies in the Biosimilar mAb Industry by Number of Compounds in Development, 2016
Table 6.2 Selected Collaborations for Biosimilar mAb Development, 2009-2015
Table 6.3 BioXpress: Compounds in the Pipeline, 2016
Table 6.4 Tests Carried Out By BioXpress During Biosimilar mAb Development, with Objectives
Table 6.5 Compounds in Celltrion’s Pipeline: Compound Name, Generic Name, Development Stage and Anticipated Year of Approval, 2016
Table 6.6 Genor Biopharma: Biosimilar mAbs Pipeline, 2016
Table 6.7 Mabion: Compounds in the Pipeline and Their Development Stage, 2016
Table 6.8 Gene Techno Science: Revenue ($m), from 2013-2015
Table 6.9 Biocon: Compounds in the Pipeline and Their Stage of Development, 2016
Table 6.10 Big Pharma's Positions in the Biosimilar mAb Industry, 2016
Table 6.11 Significant Acquisitions in the Biosimialr mAb Market 2015
Table 7.1 Strengths and Weaknesses of the Biosimilar mAb Market, 2016-2026
Table 7.2 Opportunities and Threats Facing the Biosimilar mAb Market, 2016-2026
Table 7.3 Social and Technological Factors Influencing the Biosimilar mAb Market, 2016-2026

List of Figures
Figure 1.1 Main Compound Classes of Biosimilar mAbs, 2016
Figure 2.1 Structure of an Antibody
Figure 3.1 Global Market for Biosimilar mAbs: Revenue forecast ($m), 2016-2026
Figure 3.2 The Biosimilar mAb Market: Market Share (%) by compound in 2015
Figure 3.3 The Biosimilar mAb Market: Market Share (%) by compound in 2020
Figure 3.4 The Biosimilar mAb Market: Market Share (%) by compound in 2026
Figure 3.5 Biosimilar Infliximab: Global Revenue ($m) Forecast 2016-2026
Figure 3.6 Biosimilar Rituximab: Global Revenue ($m) Forecast 2016-2026
Figure 3.7 Biosimilar Abciximab: Global Revenue ($m) Forecast 2016-2026
Figure 3.8 Biosimilar Trastuzumab: Global Revenue ($m) Forecast 2016-2026
Figure 3.9 Biosimilar Adalimumab: Global Revenue ($m) Forecast 2016-2026
Figure 3.10 Biosimilar Bevacizumab: Global Revenue ($m) Forecast 2016-2026
Figure 3.11 Drivers and Restraints for the Global Biosimilar mAb market 2016-2026
Figure 4.1 Biosimilar mAb Versions on the Market: Market Share (%) 2015
Figure 4.2 Biosimilar mAb Versions on the Market: Market Share (%) 2020
Figure 4.3 Biosimilar mAb Versions on the Market: Market Share (%) 2026
Figure 4.4 Remsima/Inflectra/Flammegis (Infliximab): Revenue Forecast ($m), 2016-2026
Figure 4.5 Remsima/Inflectra/Flammegis (Infliximab): AGR Forecast (%), 2016-2026
Figure 4.6 Infimab (Infliximab): Revenue Forecast ($m) 2016-2026
Figure 4.7 Infimab (Infliximab): AGR Forecast (%) 2016-2026
Figure 4.8 Reditux (Rituximab): Revenue Forecast ($m) 2016-2026
Figure 4.9 Reditux (Rituximab): AGR Forecast (%) 2016-2026
Figure 4.10 Mabtas (Rituximab): Revenue Forecast ($m) 2016-2026
Figure 4.11 Mabtas (Rituximab): AGR Forecast (%) 2016-2026
Figure 4.12 AcellBia (Rituximab): Revenue Forecast ($m) 2016-2026
Figure 4.13 AcellBia (Rituximab): AGR Forecast(%) 2016-2026
Figure 4.14 MABALL (Rituximab): Revenue Forecast ($m) 2016-2026
Figure 4.15 MABALL (Rituximab): AGR Forecast(%) 2016-2026
Figure 4.16 Clotinab (Abciximab): Revenue Forecast ($m) 2016-2026
Figure 4.17 Clotinab (Abciximab): AGR Forecast (%) 2016-2026
Figure 4.18 AbcixiRel (Abciximab): Revenue Forecast ($m) 2016-2026
Figure 4.19 AbcixiRel (Abciximab): AGR Forecast (%) 2016-2026
Figure 4.20 Herzuma (Trastuzumab): Revenue Forecast ($m) 2016-2026
Figure 4.21 Herzuma (Trastuzumab): AGR Forecast (%) 2016-2026
Figure 4.22 CANMAb/Hertraz (Trastuzumab): Revenue Forecast ($m) 2016-2026
Figure 4.23 CANMAb/Hertraz (Trastuzumab): AGR Forecast (%) 2016-2026
Figure 4.24 BI695500 (Rituximab): Revenue Forecast ($m) 2016-2026
Figure 4.25 BI695500 (Rituximab): AGR Forecast (%) 2018-2026
Figure 4.26 CT-P10 (Rituximab): Revenue Forecast ($m) 2016-2026
Figure 4.27 CT-P10 (Rituximab): AGR Forecast (%) 2019-2026
Figure 4.28 BI695501 (Adalimumab): Revenue Forecast ($m) 2016-2026
Figure 4.29 BI695501 (Adalimumab): AGR Forecast (%)2018-2026
Figure 4.30 BCD-022 (Trastuzumab): Revenue Forecast ($m) 2016-2026
Figure 4.31 BCD-022 (Trastuzumab): AGR Forecast (%) 2017-2026
Figure 4.32 FKB327 (Adalimumab): Revenue Forecast ($m) 2016-2026
Figure 4.33 FKB327 (Adalimumab): AGR Forecast (%) 2018-2026
Figure 4.34 FKB238 (Adalimumab): Revenue Forecast ($m) 2016-2026
Figure 4.35 FKB238 (Adalimumab): AGR Forecast(%) 2021-2026
Figure 4.36 BCD-021 (Bevacizumab): Revenue Forecast ($m) 2016-2026
Figure 4.37 BCD-021 (Bevacizumab): AGR Forecast (%) 2018-2026
Figure 5.1 The Biosimilar MAb Market by Country: Market Shares (%) of Revenue, 2015
Figure 5.2 The Biosimilar MAb Market: National Submarket Shares (%), 2020
Figure 5.3 The Biosimilar MAb Market: National Submarket Shares (%), 2026
Figure 5.4 The Indian Biosimilar mAb Market: Revenue Forecast ($m), 2016-2026
Figure 5.5 The Russian Biosimilar mAb Market: Revenue Forecast ($m), 2016-2026
Figure 5.6 The South Korean Biosimilar mAb Market: Revenue Forecast ($m), 2016-2026
Figure 5.7 The Chinese Biosimilar mAb Market: Revenue Forecast ($m), 2016-2026
Figure 5.8 The Brazilian Biosimilar mAb Market: Revenue Forecast ($m), 2016-2026
Figure 5.9 The EU5 Biosimilar mAb Market: Grouped Revenue Forecast ($m), 2016-2026
Figure 5.10 The EU5 Biosimilar mAb Market: Revenue Forecasts ($m) by Country, 2016-2026
Figure 5.11 The German Biosimilar mAb Market: Revenue Forecast ($m), 2016-2026
Figure 5.12 The French Biosimilar mAb Market: Revenue Forecast ($m), 2016-2026
Figure 5.13 The UK Biosimilar mAb Market: Revenue Forecast ($m), 2016-2026
Figure 5.14 The Italian Biosimilar mAb Market: Revenue Forecast ($m), 2016-2026
Figure 5.15 The Spanish Biosimilar mAb Market: Revenue Forecast ($m), 2016-2026
Figure 5.16 The Japanese Biosimilar mAb Market: Revenue Forecast ($m), 2016-2026
Figure 5.17 Biosimilar mAbs in the US: Revenue Forecast ($m), 2016-2026
Figure 6.1 Prominent Companies in the Biosimilar mAb Industry: Share (%) of the Pipeline,
Figure 9.1 Prominent Compounds in the Biosimilar mAb Market: Comparison of Revenues ($m), 2015, 2020 and 2026
Figure 9.2 Forecasted Biosimilar mAbs: Comparison of Revenues ($m), 2015, 2020 and 2026
Figure 9.3 Leading National Markets: Revenues ($m), 2015, 2020 and 2026
Figure 9.4 Prominent Companies in the Biosimilar mAb Industry: Number of Products in Current Development or in the Pipeline, 2016

【レポートのキーワード】

バイオシミラー・モノクローナル抗体、インフリキシマブ、リツキシマブ、トラスツズマブ、アダリムマブ、ベバシズマブ、アブシキシマブ、医薬品

★調査レポート[バイオシミラー・モノクローナル抗体の世界市場:インフリキシマブ、リツキシマブ、トラスツズマブ、アダリムマブ、ベバシズマブ、アブシキシマブ] ( Biosimilar Monoclonal Antibodies Market Forecast 2016-2026 : Biosimilar Versions of Infliximab, Rituximab, Trastuzumab, Adalimumab, Bevacizumab and Abciximab / VGAIN6041527) 販売に関する免責事項
[バイオシミラー・モノクローナル抗体の世界市場:インフリキシマブ、リツキシマブ、トラスツズマブ、アダリムマブ、ベバシズマブ、アブシキシマブ] ( Biosimilar Monoclonal Antibodies Market Forecast 2016-2026 : Biosimilar Versions of Infliximab, Rituximab, Trastuzumab, Adalimumab, Bevacizumab and Abciximab / VGAIN6041527) についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆